ClinicalTrials.gg
CompletedNCT05437510Updated Oct 9, 2025Results posted

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

A Phase 3 interventional study of Nirsevimab in RSV Immunization and Healthy Volunteer, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 240 sites in 3 countries. Open to participants aged 0 Days to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,057
Allocation
Randomized
Ages
0 Days to 12 Months
Sex
All
01

Study summary

The purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who were not eligible to receive palivizumab.

The visit frequency was 1 in-person dosing/randomization visit, with monthly safety follow-up electronic contacts through the first 6 months post dosing/randomization for all participants. The study also included a 12-month (Day 366) follow-up telephone call. The D366 follow-up telephone call was the final follow-up telephone call for France, Germany and UK non-reconsented participants. The study included an 18-month (D546) and a 24-month (D731, final telephone call) follow-up telephone call for UK reconsented participants.

Read the detailed description

12 months post-dosing/randomization for France, Germany and UK non-reconsented participants, 24 months post-dosing/randomization for UK reconsented participants. D01 was the day of randomization (both study groups) and immunization (nirsevimab group).

02

Conditions studied

  • RSV Immunization
  • Healthy Volunteer
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born at ≥ 29 weeks gestational age and aged 0 to 12 months (calendar age), who entered their first RSV season on the day of inclusion in the study (D01)
  • form was signed and dated by the parent(s) or other LAR(s) (and by an independent witness if required by local regulations)
  • Participant and parent/LAR were able to attend the scheduled visit and to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • Participants were not eligible for the study if any of the following criteria are met:
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Active confirmed RSV infection at the time of dosing/randomization
  • Active LRTI at the time of dosing/randomization
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Laboratory confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent/LAR, contraindicating intramuscular injection
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection
  • Any condition that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration.
  • A prospective participant was not included in the study until the condition has resolved or the febrile event has subsided
  • Mother of the infant participant was administered an RSV vaccine during her pregnancy with the infant participant
  • Receipt of any monoclonal antibody by the infant participant
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months by the infant participant
  • Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Eligible to receive palivizumab at time of inclusion (as per local guidelines)
  • In an emergency setting or hospitalized involuntarily
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study

The above information were not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,057 participants (actual)

Study arms

  • Experimental
    Nirsevimab

    1 intramuscular injection at Day 01

    Biological: Nirsevimab

  • No intervention
    No preventive intervention for RSV

    No intervention

Interventions

  • BiologicalNirsevimab

    Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular

06

What researchers measure

Primary outcomes

  1. Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths per minute (/min); 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection.

    Time frame: From dosing/randomization (Day 1) up to approximately 7 months

Secondary outcomes

  1. Number of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Very severe RSV LRTI was defined as RSV LRTI hospitalization with oxygen saturation \<90% (at any time during hospitalization) and oxygen supplementation. Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection.

    Time frame: From dosing/randomization (Day 1) up to approximately 7 months

  2. Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through the Respiratory Syncytial Virus Season in Each Country

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection. Number of participants with RSV LRTI hospitalization through the RSV season in France, UK, and Germany is presented.

    Time frame: From dosing/randomization (Day 1) up to approximately 7 months

  3. Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection. Number of participants with hospitalization for all-cause LRTI through the RSV season in France, UK, Germany, and overall is presented.

    Time frame: From dosing/randomization (Day 1) up to approximately 7 months

  4. Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through 151 Days Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization through 151 days post-dosing/randomization in France, UK, Germany, and overall is presented.

    Time frame: From dosing/randomization (Day 1) to Day 151

  5. Number of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through 151 Days Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Very severe RSV LRTI was defined as RSV LRTI hospitalization with oxygen saturation \<90% (at any time during hospitalization) and oxygen supplementation. Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with very severe RSV LRTI through 151 days post-dosing/randomization in France, UK, Germany, and overall is presented.

    Time frame: From dosing/randomization (Day 1) to Day 151

  6. Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through 151 Days Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI through 151 days post-dosing/randomization in France, UK, Germany, and overall is presented.

    Time frame: From dosing/randomization (Day 1) to Day 151

  7. Number of Participants With Immediate Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were either events with the start date and time posterior to the start of the treatment period and up to the end of the treatment period or events with the start date and time prior to the start of the treatment period, whose severity was greater than 1 or missing and stop date is missing or not before the treatment period. Immediate events were recorded to capture medically relevant AEs which occurred within the first 30 minutes after immunization.

    Time frame: Up to 30 minutes post-dosing/randomization on Day 1

  8. Number of Participants With Non-Serious Treatment-Emergent Adverse Events

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were either events with the start date and time posterior to the start of the treatment period and up to the end of the treatment period or events with the start date and time prior to the start of the treatment period, whose severity was greater than 1 or missing and stop date was missing or not before the treatment period.

    Time frame: From dosing/randomization (Day 1) to Day 31

  9. Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs) and Treatment-Emergent Medically Attended Adverse Events (MAAEs)

    AE: untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not related to it. TEAEs: events with start date/time posterior to start of treatment period(TP) and up to end of TP, or events with start date/time prior to start of TP, whose severity was\>1/missing; stop date was missing/not before TP. SAE: AE at any dose resulting in death, persistent or significant disability/incapacity, required inpatient hospitalization/prolongation of existing hospitalization, was life-threatening or congenital anomaly/birth defect or medically important event. MAAE: new onset/worsening of condition that prompted participant or participant's parent/legally acceptable representative to seek unplanned medical advice at physician's office/Emergency Department. AESI: scientific, medical concern specific to Sponsor's study intervention/program for which ongoing monitoring and rapid communication by investigator to Sponsor was appropriate.

    Time frame: From dosing/randomization (Day 1) to Day 366

  10. Number of Participants With Treatment-Related Serious Adverse Event (for United Kingdom Reconsented Participants)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were either events with the start date and time posterior to the start of the treatment period and up to the end of the treatment period or events with the start date and time prior to the start of the treatment period, whose severity was greater than 1 or missing and stop date is missing or not before the treatment period. SAE: AE at any dose resulting in death, persistent or significant disability/incapacity, required inpatient hospitalization/prolongation of existing hospitalization, was life-threatening or congenital anomaly/birth defect or medically important event. A treatment-related TEAE was a TEAE considered by the investigator as related or with unknown/missing relationship to treatment for participants who received nirsevimab on Day 1.

    Time frame: From Day 366 to Day 731

  11. Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through 181 Days Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization through 181 days post-dosing/randomization in France, UK, Germany, and overall is presented.

    Time frame: From dosing/randomization (Day 1) to Day 181

  12. Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through 181 Days Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI through 181 days post-dosing/randomization in France, UK, Germany, and overall is presented.

    Time frame: From dosing/randomization (Day 1) to Day 181

  13. Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 181 to 366 Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization from Days 181 to 366 post-dosing/randomization (with no RSV LRTI hospitalizations before Day 181) in France, UK, Germany, and overall is presented.

    Time frame: From Day 181 to Day 366

  14. Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 181 to 366 Post-dosing/Randomization

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI from Days 181 to 366 post-dosing/randomization (with no hospitalizations for all-cause LRTI before Day 181) is presented.

    Time frame: From Day 181 to Day 366

  15. Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization from Days 366 to 731 post-dosing/randomization (with no RSV LRTI hospitalizations before Day 366) in UK reconsented participants is presented.

    Time frame: From Day 366 to Day 731

  16. Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)

    LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI from Days 366 to 731 post-dosing/randomization (with no hospitalizations for all-cause LRTI before Day 366) in UK reconsented participants is presented.

    Time frame: From Day 366 to Day 731

  17. Number of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants)

    Wheeze was defined as a physician-diagnosed wheeze or asthma or related ear, nose and throat (ENT)/respiratory symptoms at an office visit or an illness for which the child was prescribed medication to treat an ENT/respiratory condition. Recurrent wheeze event was defined as 2 or more protocol-defined wheeze episodes throughout follow-up period.

    Time frame: From dosing/randomization (Day 1) to Day 731

07

Results

Posted Apr 11, 2025

Participant flow

The study was conducted at 235 investigational sites in France, Germany and the United Kingdom (UK).

Participant flow — Overall Study
MilestoneNirsevimabNo Intervention
Started40384019
Randomized and treated40151
Participants entered study extension11421084
Completed37473631
Not completed291388
Withdrew: Adverse event21
Withdrew: Protocol deviation16
Withdrew: Withdrawal by parent/guardian2323
Withdrew: Lost to follow-up265358

Outcome measures

PrimaryNumber of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths per minute (/min); 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection.

Time frame:
From dosing/randomization (Day 1) up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season
ParticipantsNirsevimabNo Intervention
Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season1164
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 84.04 · 95% CI 69.493 to 92.411
SecondaryNumber of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Very severe RSV LRTI was defined as RSV LRTI hospitalization with oxygen saturation \<90% (at any time during hospitalization) and oxygen supplementation. Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection.

Time frame:
From dosing/randomization (Day 1) up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season
ParticipantsNirsevimabNo Intervention
Number of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season521
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0014 · Efficacy: 77.71 · 95% CI 39.249 to 93.432
SecondaryNumber of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through the Respiratory Syncytial Virus Season in Each Country

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection. Number of participants with RSV LRTI hospitalization through the RSV season in France, UK, and Germany is presented.

Time frame:
From dosing/randomization (Day 1) up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through the Respiratory Syncytial Virus Season in Each Country
ParticipantsNirsevimabNo Intervention
France328
United Kingdom317
Germany519
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 (Adjusted p-value is reported.) · Efficacy: 90.70 · 95% CI 63.676 to 98.813
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0036 (Adjusted p-value is reported.) · Efficacy: 83.20 · 95% CI 33.589 to 97.593
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0051 (Adjusted p-value is reported.) · Efficacy: 74.62 · 95% CI 29.740 to 92.595
SecondaryNumber of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. RSV season was the period of increased RSV infection. Number of participants with hospitalization for all-cause LRTI through the RSV season in France, UK, Germany, and overall is presented.

Time frame:
From dosing/randomization (Day 1) up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season
ParticipantsNirsevimabNo Intervention
Overall48106
France2444
United Kingdom1739
Germany723
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 57.97 · 95% CI 40.360 to 70.760
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0039 · Efficacy: 52.48 · 95% CI 20.121 to 72.360
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0024 · Efficacy: 58.62 · 95% CI 25.115 to 78.049
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0037 · Efficacy: 70.74 · 95% CI 29.567 to 89.396
SecondaryNumber of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through 151 Days Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization through 151 days post-dosing/randomization in France, UK, Germany, and overall is presented.

Time frame:
From dosing/randomization (Day 1) to Day 151
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through 151 Days Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Overall1267
France428
United Kingdom320
Germany519
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 82.44 · 95% CI 67.271 to 91.357
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 86.11 · 95% CI 60.283 to 96.459
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0004 · Efficacy: 85.20 · 95% CI 50.084 to 97.183
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0055 · Efficacy: 74.36 · 95% CI 29.006 to 92.518
SecondaryNumber of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through 151 Days Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Very severe RSV LRTI was defined as RSV LRTI hospitalization with oxygen saturation \<90% (at any time during hospitalization) and oxygen supplementation. Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with very severe RSV LRTI through 151 days post-dosing/randomization in France, UK, Germany, and overall is presented.

Time frame:
From dosing/randomization (Day 1) to Day 151
Reported as:
Count of participants · Participants
Number of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through 151 Days Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Overall624
France29
United Kingdom111
Germany34
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0013 · Efficacy: 75.31 · 95% CI 38.012 to 91.747
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0620 · Efficacy: 78.10 · 95% CI -5.823 to 97.697
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0060 · Efficacy: 91.01 · 95% CI 38.156 to 99.791
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.9851 · Efficacy: 26.01 · 95% CI -337.329 to 89.162
SecondaryNumber of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through 151 Days Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI through 151 days post-dosing/randomization in France, UK, Germany, and overall is presented.

Time frame:
From dosing/randomization (Day 1) to Day 151
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through 151 Days Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Overall76132
France3248
United Kingdom3558
Germany926
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 43.62 · 95% CI 24.677 to 58.057
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0754 · Efficacy: 34.78 · 95% CI -4.148 to 59.648
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0177 · Efficacy: 40.67 · 95% CI 8.211 to 62.156
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0046 · Efficacy: 66.38 · 95% CI 25.952 to 86.137
SecondaryNumber of Participants With Immediate Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were either events with the start date and time posterior to the start of the treatment period and up to the end of the treatment period or events with the start date and time prior to the start of the treatment period, whose severity was greater than 1 or missing and stop date is missing or not before the treatment period. Immediate events were recorded to capture medically relevant AEs which occurred within the first 30 minutes after immunization.

Time frame:
Up to 30 minutes post-dosing/randomization on Day 1
Reported as:
Count of participants · Participants
Number of Participants With Immediate Treatment-Emergent Adverse Events (TEAEs)
ParticipantsNirsevimabNo Intervention
Number of Participants With Immediate Treatment-Emergent Adverse Events (TEAEs)270
SecondaryNumber of Participants With Non-Serious Treatment-Emergent Adverse Events

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were either events with the start date and time posterior to the start of the treatment period and up to the end of the treatment period or events with the start date and time prior to the start of the treatment period, whose severity was greater than 1 or missing and stop date was missing or not before the treatment period.

Time frame:
From dosing/randomization (Day 1) to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Non-Serious Treatment-Emergent Adverse Events
ParticipantsNirsevimabNo Intervention
Number of Participants With Non-Serious Treatment-Emergent Adverse Events13161265
SecondaryNumber of Participants With Treatment-Emergent Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs) and Treatment-Emergent Medically Attended Adverse Events (MAAEs)

AE: untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not related to it. TEAEs: events with start date/time posterior to start of treatment period(TP) and up to end of TP, or events with start date/time prior to start of TP, whose severity was\>1/missing; stop date was missing/not before TP. SAE: AE at any dose resulting in death, persistent or significant disability/incapacity, required inpatient hospitalization/prolongation of existing hospitalization, was life-threatening or congenital anomaly/birth defect or medically important event. MAAE: new onset/worsening of condition that prompted participant or participant's parent/legally acceptable representative to seek unplanned medical advice at physician's office/Emergency Department. AESI: scientific, medical concern specific to Sponsor's study intervention/program for which ongoing monitoring and rapid communication by investigator to Sponsor was appropriate.

Time frame:
From dosing/randomization (Day 1) to Day 366
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs) and Treatment-Emergent Medically Attended Adverse Events (MAAEs)
ParticipantsNirsevimabNo Intervention
Treatment-emergent SAEs262222
Treatment-emergent AESIs113
Treatment-emergent MAAEs31063100
SecondaryNumber of Participants With Treatment-Related Serious Adverse Event (for United Kingdom Reconsented Participants)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were either events with the start date and time posterior to the start of the treatment period and up to the end of the treatment period or events with the start date and time prior to the start of the treatment period, whose severity was greater than 1 or missing and stop date is missing or not before the treatment period. SAE: AE at any dose resulting in death, persistent or significant disability/incapacity, required inpatient hospitalization/prolongation of existing hospitalization, was life-threatening or congenital anomaly/birth defect or medically important event. A treatment-related TEAE was a TEAE considered by the investigator as related or with unknown/missing relationship to treatment for participants who received nirsevimab on Day 1.

Time frame:
From Day 366 to Day 731
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Serious Adverse Event (for United Kingdom Reconsented Participants)
ParticipantsNirsevimabNo Intervention
Number of Participants With Treatment-Related Serious Adverse Event (for United Kingdom Reconsented Participants)00
SecondaryNumber of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through 181 Days Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization through 181 days post-dosing/randomization in France, UK, Germany, and overall is presented.

Time frame:
From dosing/randomization (Day 1) to Day 181
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization Through 181 Days Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Overall1268
France428
United Kingdom321
Germany519
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 82.72 · 95% CI 67.826 to 91.490
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 86.13 · 95% CI 60.340 to 96.464
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0002 · Efficacy: 85.92 · 95% CI 52.850 to 97.311
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0054 · Efficacy: 74.39 · 95% CI 29.077 to 92.525
SecondaryNumber of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through 181 Days Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI through 181 days post-dosing/randomization in France, UK, Germany, and overall is presented.

Time frame:
From dosing/randomization (Day 1) to Day 181
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection Through 181 Days Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Overall82138
France3449
United Kingdom3862
Germany1027
Statistical analysis
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = <0.0001 · Efficacy: 41.89 · 95% CI 23.073 to 56.333
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.1003 · Efficacy: 32.19 · 95% CI -7.188 to 57.545
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0164 · Efficacy: 39.83 · 95% CI 8.449 to 60.911
  • Nirsevimab vs No Intervention · Exact method using binomial distribution · p = 0.0058 · Efficacy: 64.06 · 95% CI 23.386 to 84.478
SecondaryNumber of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 181 to 366 Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization from Days 181 to 366 post-dosing/randomization (with no RSV LRTI hospitalizations before Day 181) in France, UK, Germany, and overall is presented.

Time frame:
From Day 181 to Day 366
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 181 to 366 Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Overall3128
France65
United Kingdom2019
Germany54
SecondaryNumber of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 181 to 366 Post-dosing/Randomization

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI from Days 181 to 366 post-dosing/randomization (with no hospitalizations for all-cause LRTI before Day 181) is presented.

Time frame:
From Day 181 to Day 366
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 181 to 366 Post-dosing/Randomization
ParticipantsNirsevimabNo Intervention
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 181 to 366 Post-dosing/Randomization6855
SecondaryNumber of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with RSV LRTI hospitalization from Days 366 to 731 post-dosing/randomization (with no RSV LRTI hospitalizations before Day 366) in UK reconsented participants is presented.

Time frame:
From Day 366 to Day 731
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)
ParticipantsNirsevimabNo Intervention
Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)72
SecondaryNumber of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)

LRTI included the following common symptoms: clinical finding of rhonchi, rales, crackles, or wheeze; increased respiratory rate at rest (age: \<2 months, ≥60 breaths/min; 2 to 6 months, ≥50 breaths/min; \>6 months, ≥40 breaths/min), and hypoxemia (in room air: oxygen saturation \<95%). Hospitalization was defined as the decision to admit to in-patient care by the treating physician. Number of participants with hospitalization for all-cause LRTI from Days 366 to 731 post-dosing/randomization (with no hospitalizations for all-cause LRTI before Day 366) in UK reconsented participants is presented.

Time frame:
From Day 366 to Day 731
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)
ParticipantsNirsevimabNo Intervention
Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)1810
SecondaryNumber of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants)

Wheeze was defined as a physician-diagnosed wheeze or asthma or related ear, nose and throat (ENT)/respiratory symptoms at an office visit or an illness for which the child was prescribed medication to treat an ENT/respiratory condition. Recurrent wheeze event was defined as 2 or more protocol-defined wheeze episodes throughout follow-up period.

Time frame:
From dosing/randomization (Day 1) to Day 731
Reported as:
Count of participants · Participants
Number of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants)
ParticipantsNirsevimabNo Intervention
Number of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants)10196

Adverse events

Collected over SAEs and all-cause mortality were collected from dosing/randomization (Day 1) up to end of follow-up (Day 366 for France, Germany, UK non-reconsented participants and Day 731 for UK reconsented participants). Non-serious AEs were collected from dosing/randomization (Day 1) up to Day 31 as pre-specified in protocol.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nirsevimab1/4,016 (0%)262/4,016 (6.5%)324/4,016 (8.1%)
No Intervention0/4,018 (0%)222/4,018 (5.5%)279/4,018 (6.9%)
Most frequent serious events
Showing 10 of 235
Most frequent serious events
EventNirsevimabNo Intervention
GastroenteritisInfections and infestations11/401612/4018
SeizureNervous system disorders11/40163/4018
Viral InfectionInfections and infestations11/40167/4018
PyrexiaGeneral disorders9/401611/4018
Febrile ConvulsionNervous system disorders10/401610/4018
PyelonephritisInfections and infestations10/40169/4018
Upper Respiratory Tract InfectionInfections and infestations10/40169/4018
InfluenzaInfections and infestations8/40166/4018
Covid-19Infections and infestations6/40168/4018
TonsillitisInfections and infestations7/40162/4018
Most frequent other events
Most frequent other events
EventNirsevimabNo Intervention
NasopharyngitisInfections and infestations324/4016279/4018

Baseline characteristics

The All Randomized Set consisted of all participants randomly assigned to either the nirsevimab group or the no intervention group.

Age, Continuous
Age, Continuous(months)NirsevimabNo InterventionTotal
Mean4.53 ± 3.3424.48 ± 3.2944.51 ± 3.318
Sex: Female, Male
Sex: Female, Male(Participants)NirsevimabNo InterventionTotal
Female195019123862
Male208821074195
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)NirsevimabNo InterventionTotal
Count of participants——0
08

Study locations

240 sites
  • Investigational Site 2500041
    Aix-en-Provence, 13100, France
  • Investigational Site 2500002
    Amiens, 80054, France
  • Investigational Site Number: 2500014
    Bordeaux, 33076, France
  • Investigational Site 2500007
    Brest, 29200, France
  • Investigational Site Number: 2500038
    Brest, 29200, France
  • Investigational Site Number: 2500045
    Brest, 29200, France
  • Investigational Site Number: 2500019
    Bron, 69677, France
  • Investigational Site Number: 2500043
    Brumath, 67170, France
  • Investigational Site Number: 2500001
    Caen, 14033, France
  • Investigational Site Number: 2500032
    Chambéry, 73000, France
  • Investigational Site Number: 2500057
    Clamart, 92140, France
  • Investigational Site Number: 2500065
    Clamart, 92140, France
  • Investigational Site Number: 2500029
    Combs-la-Ville, 77380, France
  • Investigational Site Number: 2500013
    Corbeil-Essonnes, 91100, France
  • Investigational Site Number: 2500054
    Creil, 60100, France
  • Investigational Site Number: 2500006
    Créteil, 94010, France
  • Investigational Site Number: 2500039
    Créteil, 94010, France
  • Investigational Site Number: 2500023
    Dijon, 21000, France
  • Investigational Site Number: 2500069
    Draguignan, 83300, France
  • Investigational Site 2500008
    Essey-lès-Nancy, 54270, France
  • Investigational Site 2500030
    Étampes, 91150, France
  • Investigational Site Number: 2500058
    Frouard, 54390, France
  • Investigational Site Number: 2500064
    Grasse, 06135, France
  • Investigational Site Number: 2500004
    Grenoble, 38043, France
  • Investigational Site Number: 2500027
    Héry-sur-Alby, 74540, France
  • Investigational Site Number: 2500060
    Huningue, 68330, France
  • Investigational Site 2500059
    La Garenne-Colombes, 92250, France
  • Investigational Site Number: 2500071
    La Teste-de-Buch, 33260, France
  • Investigational Site Number: 2500034
    Le Kremlin-Bicêtre, 94270, France
  • Investigational Site Number: 2500072
    Libourne, 33500, France
  • Investigational Site 2500046
    Lille, 59000, France
  • Investigational Site 2500005
    Lille, 59037, France
  • Investigational Site Number: 2500012
    Limoges, 87042, France
  • Investigational Site Number: 2500037
    Longjumeau, 91160, France
  • Investigational Site 2500021
    Maromme, 76150, France
  • Investigational Site Number: 2500003
    Marseille, 13015, France
  • Investigational Site Number: 2500073
    Marseille, 13385, France
  • Investigational Site Number: 2500068
    Mont-de-Marsan, 40000, France
  • Investigational Site Number: 2500066
    Mont-Saint-Aignan, 76130, France
  • Investigational Site Number: 2500067
    Montpellier, 34295, France
  • Investigational Site Number: 2500077
    Morlaix, 29600, France
  • Investigational Site Number: 2500047
    Nantes, 44093, France
  • Investigational Site Number: 2500055
    Nice, 06200, France
  • Investigational Site Number: 2500009
    Nice, 06300, France
  • Investigational Site Number: 2500040
    Nogent-sur-Marne, 94130, France
  • Investigational Site Number: 2500022
    Orléans, 45000, France
  • Investigational Site Number: 2500050
    Orléans, 45067, France
  • Investigational Site Number: 2500024
    Paris, 75011, France
  • Investigational Site Number: 2500010
    Paris, 75012, France
  • Investigational Site Number: 2500075
    Paris, 75012, France
  • Investigational Site Number: 2500051
    Paris, 75016, France
  • Investigational Site Number:
    Pau, 64000, France
  • Investigational Site Number: 2500018
    Poissy, 78300, France
  • Investigational Site Number: 2500026
    Puteaux, 92800, France
  • Investigational Site Number: 2500042
    Rouen, 76000, France
  • Investigational Site Number: 2500078
    Saint-Doulchard, 18230, France
  • Investigational Site Number: 2500074
    Saint-Julien-en-Genevois, 74160, France
  • Investigational Site Number: 2500044
    Saint-Maur-des-Fossés, 94100, France
  • Investigational Site 2500020
    Saint-Sébastien-sur-Loire, 44230, France
  • Investigational Site Number: 2500052
    Saverne, 67700, France
  • Investigational Site Number: 2500015
    Toulouse, 31059, France
  • Investigational Site Number: 2500035
    Tours, 37000, France
  • Investigational Site Number: 2500049
    Vendenheim, 67550, France
  • Investigational Site Number: 2500011
    Villeneuve-lès-Avignon, 30400, France
  • Investigational Site Number: 2500063
    Villeneuve-Saint-Georges, 94195, France
  • Investigational Site 2500028
    Vincennes, 94300, France
  • Investigational Site Number: 2760036
    Augsburg, 86154, Germany
  • Investigational Site Number: 2760017
    Bad Wildungen, 34537, Germany
  • Investigational Site Number: 2760099
    Berlin, 10551, Germany
  • Investigational Site Number: 2760076
    Berlin, 13353, Germany
  • Investigational Site Number: 2760056
    Berlin, 13589, Germany
  • Investigational Site Number: 2760050
    Bielefeld, 33617, Germany
  • Investigational Site Number: 2760064
    Bocholt, 46397, Germany
  • Investigational Site Number: 2760098
    Bochum, 44791, Germany
  • Investigational Site Number: 2760040
    Bonn, 53127, Germany
  • Investigational Site Number: 2760025
    Bramsche, 49565, Germany
  • Investigational Site Number: 2760018
    Braunschweig, 38118, Germany
  • Investigational Site Number: 2760051
    Detmold, 32756, Germany
  • Investigational Site Number: 2760085
    Dortmund, 44137, Germany
  • Investigational Site Number: 2760059
    Düsseldorf, 40217, Germany
  • Investigational Site Number: 2760101
    Düsseldorf, 40589, Germany
  • Investigational Site Number: 2760081
    Eckental, 90542, Germany
  • Investigational Site Number: 2760045
    Erfurt, 99086, Germany
  • Investigational Site Number: 2760047
    Forchheim, 91301, Germany
  • Investigational Site Number: 2760030
    Frankfurt (Oder), 15236, Germany
  • Investigational Site Number: 2760015
    Freiburg I. Breisgau, 79106, Germany
  • Investigational Site Number: 2760079
    Gera, 07548, Germany
  • Investigational Site Number: 2760005
    Gilching, 82205, Germany
  • Investigational Site Number: 2760016
    Göttingen, 37075, Germany
  • Investigational Site Number: 2760060
    Göttingen, 37075, Germany
  • Investigational Site Number: 2760033
    Hamburg, 20251, Germany
  • Investigational Site Number: 2760057
    Hamburg, 20357, Germany
  • Investigational Site Number: 2760096
    Hamburg, 22415, Germany
  • Investigational Site Number: 2760032
    Hamm, 59063, Germany
  • Investigational Site Number: 2760007
    Hanover, 30625, Germany
  • Investigational Site Number: 2760049
    Heidelberg, 69120, Germany
  • Investigational Site Number: 2760008
    Herford, 32049, Germany
  • Investigational Site 2760010
    Hürth, 50354, Germany
  • Investigational Site Number: 2760091
    Hürth, 50354, Germany
  • Investigational Site Number: 2760035
    Itzehoe, 25524, Germany

Showing the first 100 of 240 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Munro APS, Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Vassilouthis NC, Carreno M, Moreau C, Bourron P, Marcelon L, Mari K, Roberts M, Tissieres P, Royal S, Faust SN; HARMONIE Study Group. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6. PubMed 40379431 ↗
  • Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissieres P, Royal S, Faust SN; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189. PubMed 38157500 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Mar 2024, 19 months.

Results were first posted in Apr 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Jun 29, 2022
StartActual
Aug 8, 2022
Primary completionActual
Mar 27, 2024
CompletionActual
Apr 9, 2025
Results first posted
Apr 11, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05437510
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Aug 8, 2022
Primary completion
Mar 27, 2024
Completion
Apr 9, 2025
Results posted
Apr 11, 2025
Last update
Oct 9, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion